Abstract:The basement membrane of skeletal muscle (myomatrix) consists of a complex network of highly glycosylated proteins. Important components of the myomatrix are the laminins and the collagens. During development, the myomatrix is assembled by interactions with cell surface receptors and by self-polymerization, which results in an extracellular scaffold important for skeletal muscle stability. Mutations in the α2 chain of laminin-211 impinge on myomatrix assembly and its interaction with cell surface receptors, and result in one of the most severe forms of congenital muscular dystrophy (MDC1A). Based on a detailed mechanistic understanding of the function of laminin-211, we have designed artificial linker molecules derived from agrin or perlecan with the aim to bridge the remaining myomatrix to cell surface receptors. In the conducted preclinical, proof-of-concept studies we were able to show that they can substantially ameliorate the disease phenotype in a mouse model of MDC1A. Subsequent approaches to further improve the treatment have focused on testing interventions that affect downstream pathways, such as apoptosis and inflammation, using pharmacological and genetic tools. All those treatments show additional beneficial effects on disease progression. However, semi-quantitative comparison of the treatments indicates that interventions that target early events in the disease are more efficacious than those targeting further downstream pathways. Finally, we will also report on the ongoing efforts to combine interventions that boost myomatrix assembly with those that connect it to skeletal muscle receptors. In summary, we will report on proof-of-concept studies that provide mechanistic insights and unequivocal preclinical evidence for the potential use of those therapies. As the MDC1A mice used in our studies share many hallmarks with the human disease, these preclinical data may be of high predictive value for future clinical studies. The basement membrane of skeletal muscle (myomatrix) consists of a complex network of highly glycosylated proteins. Important components of the myomatrix are the laminins and the collagens. During development, the myomatrix is assembled by interactions with cell surface receptors and by self-polymerization, which results in an extracellular scaffold important for skeletal muscle stability. Mutations in the α2 chain of laminin-211 impinge on myomatrix assembly and its interaction with cell surface receptors, and result in one of the most severe forms of congenital muscular dystrophy (MDC1A). Based on a detailed mechanistic understanding of the function of laminin-211, we have designed artificial linker molecules derived from agrin or perlecan with the aim to bridge the remaining myomatrix to cell surface receptors. In the conducted preclinical, proof-of-concept studies we were able to show that they can substantially ameliorate the disease phenotype in a mouse model of MDC1A. Subsequent approaches to further improve the treatment have focused on testing interventions that affect downstream pathways, such as apoptosis and inflammation, using pharmacological and genetic tools. All those treatments show additional beneficial effects on disease progression. However, semi-quantitative comparison of the treatments indicates that interventions that target early events in the disease are more efficacious than those targeting further downstream pathways. Finally, we will also report on the ongoing efforts to combine interventions that boost myomatrix assembly with those that connect it to skeletal muscle receptors. In summary, we will report on proof-of-concept studies that provide mechanistic insights and unequivocal preclinical evidence for the potential use of those therapies. As the MDC1A mice used in our studies share many hallmarks with the human disease, these preclinical data may be of high predictive value for future clinical studies.

Structure and mechanism of LARGE1 matriglycan polymerase

POMK regulates dystroglycan function via LARGE1-mediated elongation of matriglycan

Conformation and Dynamics of the C-terminal Region in Human Phosphoglycerate Mutase 1

Cell surface glycan engineering reveals that matriglycan alone can recapitulate dystroglycan binding and function

G.P.212

The underlying mechanisms of arenaviral entry through matriglycan

Native DGC structure rationalizes muscular dystrophy-causing mutations

Structural insights into how GlcNAc-1-phosphotransferase directs lysosomal protein transport

Myofiber-type-dependent 'boulder' or 'multitudinous Pebble' Formations Across Distinct Amylopectinoses.

Structure and assembly of the dystrophin glycoprotein complex

Structural analysis of a trimeric assembly of the mitochondrial dynamin-like GTPase Mgm1

Polymerizing laminins in development, health, and disease

Structure of a truncated human GlcNAc-1-phosphotransferase variant reveals the basis for its hyperactivity

M.I.3 The role of laminins in myomatrix assembly and skeletal muscle stability

Regulatory Role of One Critical Catalytic Loop of Polypeptide N-Acetyl-Galactosaminyltransferase-2 in Substrate Binding and Catalysis During Mucin-Type O-Glycosylation

A lamin A/C variant causing striated muscle disease provides insights into filament organization

Mfn1 Structures Reveal Nucleotide-Triggered Dimerization Critical for Mitochondrial Fusion

Linker Molecules Between Laminins and Dystroglycan Ameliorate Laminin-Alpha 2-Deficient Muscular Dystrophy at All Disease Stages

Molecular Structure and Enzymatic Mechanism of the Human Collagen Hydroxylysine Galactosyltransferase GLT25D1/COLGALT1

Glycosylation of α-dystroglycan: O-mannosylation influences the subsequent addition of GalNAc by UDP-GalNAc polypeptide N-acetylgalactosaminyltransferases

Assembly and activation of EBV latent membrane protein 1